Magnesium ion channel or transporter (None (covers multiple distinct protein families; family members have abbreviations, e.g., TRPM6, SLC41A1, CNNM2, etc.))

Magnesium ion channels and transporters comprise a **heterogeneous group** of membrane proteins responsible for the regulated movement of Mg²⁺ ions into and out of cells and organelles[1][5][9]. These include true ion channels (such as TRPM6 and TRPM7), electroneutral or electrogenic transporters (such as the SLC41 family, CNNM family, NIPA1), P-type ATPases (in bacteria/fungi, e.g., MgtA/B), and paracellular pathways mediated by claudin proteins (e.g., Claudin-16 in renal epithelia)[1][4][5][9]. Magnesium is essential for numerous cellular processes—from providing charge stabilization to ATP to direct participation in nucleic acid and enzyme function—so transporters for Mg²⁺ are critical for systemic and intracellular homeostasis in all forms of life[4][1]. Defects or dysregulation of specific members of these transporter families result in distinct human genetic disorders affecting the nervous system, kidney, or systemic metabolism[1][9]. **Key points about the target designation:** - “**Magnesium ion channels and transporters**” refers to a large number of genetically and structurally unrelated proteins, not a single target. - For **specific, structured data capture**, use *individual gene/protein names* (e.g., “Transient receptor potential cation channel subfamily M member 7 (TRPM7)” or “Cyclin and CBS domain divalent metal cation transport mediator 2 (CNNM2)”) rather than the plural/generic label.

Other names

Magnesium transporterMg²⁺ channelMg²⁺ transporterTRPM6TRPM7SLC41A1/A2CNNM2MagT1Claudin-16 (CLDN16)CorAMgtENIPA1MMgT1MMgT2ACDP2

Drugs or substances can: - Block or modulate Mg²⁺ channel/transport activity (e.g., channel blockers/agonists, but no clinical agents exist for human Mg²⁺ channels presently)[9]. - Compete with Mg²⁺ for binding (altered Mg²⁺ homeostasis by other ions) - Upregulate or downregulate transporter expression (indirectly, e.g., by hormones) - Alter paracellular transport (e.g., mutations or experimental modulation of claudins)[9].